Jian Ding, Ph.D.
Affiliations: | University of California, Berkeley, Berkeley, CA, United States |
Google:
"Jian Ding"Mean distance: 16.14 (cluster 23) | S | N | B | C | P |
Parents
Sign in to add mentorDennis Levi | post-doc | UC Berkeley | |
Ramesh Srinivasan | post-doc | 2004-2007 | UC Irvine |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Ding J, Lu HH, Levi DM. (2024) Absolute and relative disparity mechanisms revealed by an equivalent noise analysis. Scientific Reports. 14: 6863 |
Wang M, Ding J, Levi DM, et al. (2022) The effect of spatial structure on binocular contrast perception. Journal of Vision. 22: 7 |
Chopin A, Silver MA, Sheynin Y, et al. (2021) Transfer of Perceptual Learning From Local Stereopsis to Global Stereopsis in Adults With Amblyopia: A Preliminary Study. Frontiers in Neuroscience. 15: 719120 |
Lev M, Ding J, Polat U, et al. (2021) Nearby contours abolish the binocular advantage. Scientific Reports. 11: 16920 |
Ding J, Levi DM. (2020) A unified model for binocular fusion and depth perception. Vision Research. 180: 11-36 |
Xia ZJ, Ji YC, Sun DQ, et al. (2020) SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors. Acta Pharmacologica Sinica |
Martín S, Portela JA, Ding J, et al. (2020) Evaluation of a Virtual Reality implementation of a binocular imbalance test. Plos One. 15: e0238047 |
Wang L, Ai J, Shen Y, et al. (2020) Corrigendum to "SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo" [Cancer Lett. 351 (2014) 143-50]. Cancer Letters |
Xiang HY, Chen YH, Wang Y, et al. (2020) Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives. Bioorganic & Medicinal Chemistry Letters. 127194 |
Chen Y, Bai G, Ning Y, et al. (2020) Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry. 190: 112092 |